Analysed ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) News Sources
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
29-07-2026
yahoo.com
Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...
30-07-2026
yahoo.com
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.
21-08-2026
barchart.com
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
17-09-2026
yahoo.com
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
23-09-2026
yahoo.com
NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)
24-09-2026
yahoo.com
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
25-09-2026
yahoo.com
Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
25-09-2026
yahoo.com
What is the current price of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The current price of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is $25.9.
ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) since the previous trading day is $0.39.
ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) since the previous trading day is 1.5288%.
What is the most recent average sentiment score for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The most recent average sentiment score for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The most recent sentiment for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is .
SEC-8K** Filing Available For ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.